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Neurophysins are small two- domain proteins that exhibit ligand-facilitated di-
merization and its reciprocal-stronger binding by dimer than by monomer. We
have previously reported evidence of conformational differences between un-
liganded monomer and dimer, but had not established their identity, their ori-
gin, or how they affect binding affinity.
In the present study we have determined the relative structures of a neurophysin
monomer and its dimer by NMR spectroscopy. The structures show that a num-
ber of neurophysin residues that interact with the essential tyrosine of the ligand
peptide move from locations in the unliganded monomer that are unfavorable
for binding to positions in the unliganded dimer that more closely resemble
those of the liganded state, thereby contributing to the stronger binding by di-
mer. We have also identified the origin of the dimerization-induced conforma-
tional change; i.e., the same residues that form the principal inter-domain bonds
in the monomer via side-chain interactions form the principal inter-subunit
bonds in the dimer via backbone hydrogen bonding. Steric crowding upon di-
merization leads to a modification of inter-domain interactions, a resultant
change in the relative orientation of the two domains and associated changes
in intra-domain interactions. The principal residues responsible for these inter-
actions are the Cys residues of the 28-34 disulfide bridge (amino domain) and
74-79 disulfide bridge (carboxyl domain). Strong inter-domain van der Waals
interactions between sulfur atoms appear to play important roles in determining
the relative domain orientation.
(Supported by grant GM-17528 from NIH).
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Galectins are a sub-family of lectins with a conserved carbohydrate recognition
domain (CRD) that interacts with beta-galactosides. By binding cell surface
glycoconjugates, galectin-1 is involved in cell adhesion and migration pro-
cesses and is an important regulator of tumor angiogenesis. Here, we used het-
eronuclear NMR spectroscopy and molecular modeling to investigate lactose
binding to galectin-1 and to derive solution NMR structures of galectin-1 in
the lactose bound and unbound states. Structure analysis shows that the beta-
strands and loops around the lactose binding site which are more open and
dynamic in the unbound state, fold in around the bound lactose molecule damp-
ening internal motions at that site. Analysis of titration binding data reveal that
lactose binds the two CRDs of the galectin-1 dimer with negative cooperativity.
Molecular dynamics simulations provide insight into structural dynamics of the
half-loaded lactose state and, together with NMR data, suggest that lactose
binding at one site transmits a signal through the beta-sandwich and loops to
the second binding site. Overall, our results provide new insight into galec-
tin-1 structure-function relationships and to protein-carbohydrate interactions
in general.
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The IL-2 protein is an experimentally well-characterized example of conforma-
tional plasticity in a protein-protein binding interface. Whereas the original
crystal structure of the IL-2 protein lacked a particular binding pocket at the
interface, subsequent structures of the protein complexed with small-molecule
inhibitors have shown the creation of a hydrophobic pocket in order to accom-
modate inhibitor binding poses. A new in silico fragment-based drug design
methodology (SILCS FragMaps) was applied to the original IL-2 crystal struc-
ture and has been found to recapitulate this pocket observed in the complexes.
Furthermore, the pocket is seen to have an affinity for hydrophobic fragments,
consistent with experimental inhibitor binding poses. As the SILCS FragMaps
methodology is based on explicit-water all-atom molecular dynamics simula-
tions, the methodology is able to capture both the conformational plasticity
in the IL-2 surface required for pocket formation as well as the selective parti-
tioning of small hydrophobic fragments into the pocket from bulk solution.192-Pos
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Cholesteryl ester transfer protein (CETP) is a hydrophobic glycoprotein in
plasma and facilitates the exchange of neutral lipids between various lipo-
proteins resulting in a net transport of cholesteryl ester from HDL to LDL.
Decrease in CETP activity leads to an increase of HDL cholesterol which
potentially reduces cardiovascular risk.
Human recombinant CETP (rhCETP) was purified to homogeneity by hydro-
phobic interaction chromatography and size exclusion chromatography
(SEC). The protein showed an extraordinarily high thermodynamic stability
against thermal as well as denaturant-induced unfolding.
The effects of CETP on lipoprotein profiles were characterized after in-vitro
incubation of plasma with rhCETP followed by SEC and reverse phase pro-
tein arrays. Monitoring the distribution of apolipoproteins and the cholesterol
profiles confirmed the transfer of cholesteryl ester from HDL to LDL in-
duced by CETP. In the presence of the potent CETP inhibitor torcetrapib
(1 mM) added CETP is bound to lipoproteins while free CETP can still be
detected in presence of dalcetrapib (3 mM), a compound from a different
chemical class.
14C-torcetrapib and 14C-dalcetrapib were bound to CETP immobilized on se-
pharose and incubated with excess of unlabelled compounds. 14C-dalcetrapib
bound as Dalcetrapib-thiol could only be displaced in the presence of reducing
agent by an excess of unlabeled dalcetrapib but not by torcetrapib. Dalcetrapib
did not compete for binding of 14C-torcetrapib.
Interaction studies with Surface Plasmon Resonance confirmed reversible co-
valent binding of dalcetrapib-thiol and different binding sites for dalcetrapib
and torcetrapib. In agreement with literature cysteine 13 of CETP was identi-
fied as attachment point of dalcetrapib-thiol. All data suggested that torcetrapib
and dalcetrapib bind to different sites on CETP which may be related to differ-
ences observed in their pharmacological profiles.193-Pos
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Human cholesteryl ester transfer protein (CETP), a hydrophobic glycoprotein
(476 amino acids, ~74 kDa), mediates the transfer of cholesteryl ester (CE)
from high-density lipoproteins (HDL) to apo-B containing lipoproteins (low-
density lipoproteins - LDL; very low density lipoproteins - VLDL). The crystal
structure of CETP reveals a banana-shaped protein consisting of N- and C-ter-
minal b-barrel domains, a central b-sheet, and a ~60-A˚-long hydrophobic cav-
ity. Since CETP deficiency is associated with elevated ‘good-cholesterol’
(HDL-associated) levels via delayed catabolism, as a result, CETP has become
a high interest pharmacological drug target.
Here, we investigated the mechanism of CETP-mediated neutral lipid transfer
by electron microscopy (EM), image-processing, and molecular dynamic sim-
ulations (MDS). We discovered that: 1) CETP bridges HDL and LDL/VLDL to
form a ternary complex; 2) the CETP C-terminal beta-barrel domain penetrates
partially into the LDL/VLDL surface; 3) the N-terminal beta-barrel domain
penetrates through the HDL surface and interacts with the CE core; and 4)
MDS analysis suggested that the penetrating regions of CETP are highly mo-
bile and form pores that connect to cavities running through the central axis
of the CETP molecule to generate a tunnel. The tunnel was mainly hydrophobic
and connected the distal ends through its central cavities. Thus, we proposed
CETP resembles a Chinese finger trap, in which both beta-barrel domains pen-
etrate the lipoprotein surface, resulting in pressure from both ends. The pressure
may result in the anti-twisting of the two domains, leading to opening of the
tunnel for CE transfer between HDL and LDL. The distal end of N-terminal
beta-barrel domain could be particularly important for the design of pharmaco-
logical inhibitors, as blockage of the N-terminal beta-barrel domain would
prevent CE transfer with a low probability of off target effects on normal HDL
metabolism.
